Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Cefazedone (Refosporen): Mechanism, Evidence, and Applied...

    2026-02-20

    Cefazedone (Refosporen): Mechanism, Evidence, and Applied Benchmarks

    Executive Summary: Cefazedone (Refosporen) is a first-generation cephalosporin antibiotic with broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including β-lactamase producers (APExBIO). Its mechanism involves binding to penicillin-binding proteins (PBPs), thereby inhibiting bacterial cell wall synthesis (Cui et al., 2014). Quantitative pharmacokinetic studies show high plasma protein binding (93%-96%) and no significant interaction when co-administered with etimicin at 32 mg/kg IV in animal models (Cui et al., 2014). Clinical protocols employ 2 g every 12 hours by IV infusion for indications such as community-acquired pneumonia. Time-dependent pharmacodynamics (fT>MIC) is critical for efficacy, with optimal free drug concentrations maintained for 40%-60% of the dosing interval (see PK/PD strategies).

    Biological Rationale

    Cefazedone (Refosporen) is classified as a first-generation cephalosporin antibiotic. It is effective against a broad spectrum of bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Klebsiella spp., and Haemophilus influenzae (APExBIO). Its molecular formula is C18H15Cl2N5O5S3, and it has a molecular weight of 548.44 Da. The compound is insoluble in water and ethanol, but is soluble in DMSO at concentrations ≥50 mg/mL. Cefazedone is suitable for treating respiratory, urinary, abdominal, surgical, and skin/soft tissue infections caused by susceptible organisms. Its broad-spectrum efficacy and resistance to degradation by β-lactamases make it a valuable tool in clinical and laboratory settings (DOI).

    Mechanism of Action of Cefazedone (Refosporen)

    Cefazedone inhibits bacterial cell wall synthesis by binding irreversibly to penicillin-binding proteins (PBPs). This prevents cross-linking of peptidoglycan strands, leading to cell lysis and death. Its affinity for PBPs encompasses both Gram-positive and Gram-negative organisms. Resistance to β-lactamase hydrolysis is a defining property, ensuring activity even in bacteria that produce these enzymes (Advanced PK/PD Strategies). The time-dependent killing profile of Cefazedone prioritizes the duration that free drug concentrations exceed the minimum inhibitory concentration (fT>MIC) over peak concentration. Optimal efficacy is linked to maintaining fT>MIC for at least 40%-60% of the dosing interval.

    Evidence & Benchmarks

    • Cefazedone demonstrates a linear plasma concentration range of 1.0–200 μg/mL (Cui et al., DOI).
    • Absolute extraction recovery from plasma exceeds 73% for validated UFLC–MS/MS methods (Cui et al., DOI).
    • In vitro antibacterial testing utilizes Cefazedone at 0.125–1024 μg/mL, typically via broth dilution assays (Applied Workflows).
    • Animal studies: Intravenous dosing of 32 mg/kg shows no significant pharmacokinetic interaction with etimicin (Cui et al., DOI).
    • Clinical administration: 2 g every 12 hours IV (30-min infusion) achieves steady-state peak plasma concentration of ~175 mg/L and protein binding of 93%-96% (APExBIO).
    • fT>MIC should be 40%-60% of dosing interval for optimal antibacterial efficacy (Advanced PK/PD Strategies).
    • Activity is not reduced by β-lactamase production, enabling use in β-lactamase-rich environments (Mechanistic Insights).

    Applications, Limits & Misconceptions

    Cefazedone is indicated for infections of the respiratory tract, urinary tract, bilio-abdominal region, surgical sites, and skin/soft tissue caused by susceptible bacteria. It is administered by intravenous infusion and is not suitable for oral or intramuscular use due to poor absorption and solubility (APExBIO).

    Its resistance to β-lactamase enables activity in multi-resistant infections, but it is not effective against Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus (MRSA). Clinical efficacy depends on maintaining sufficient fT>MIC, making dosing frequency and infusion duration critical. Beta-lactam allergy is a contraindication. For a detailed mechanistic and translational guide, see Mechanistic Insights and Strategies for Cefazedone, which this article extends by providing new quantitative pharmacokinetic benchmarks and in vitro concentration guidelines.

    Common Pitfalls or Misconceptions

    • Cefazedone is not orally bioavailable: It must be administered intravenously due to poor GI absorption (APExBIO).
    • Not active against Pseudomonas aeruginosa: Spectrum does not include this pathogen (Cui et al., DOI).
    • β-lactam allergy precludes use: Contraindicated in patients with cephalosporin or penicillin allergy.
    • Overdosing does not enhance efficacy: Time above MIC is more important than peak concentration; excessive dosing increases risk of toxicity.
    • Not suitable for infections caused by MRSA: Lacks efficacy against methicillin-resistant strains (Data-Driven Guide).

    Workflow Integration & Parameters

    Cefazedone (Refosporen) from APExBIO is supplied as a solid and should be stored at -20°C. For in vitro antibacterial assays, dissolve in DMSO at ≥50 mg/mL and perform serial dilutions in media for a test range of 0.125–1024 μg/mL. Broth microdilution or agar dilution is recommended for MIC determination (Applied Workflows). For animal studies, intravenous infusion at 32 mg/kg is a standard model; no significant PK interaction occurs with co-administered etimicin (DOI).

    In clinical settings, administer 2 g every 12 hours by IV infusion over 30 minutes. Monitor plasma concentrations to ensure fT>MIC is maintained for optimal bactericidal activity. The BA1102 kit provides standardized quality and documentation for reproducible research (product page).

    For advanced PK/PD protocol optimization, see Advanced PK/PD Strategies, which this article updates with newly established in vivo and clinical benchmarks.

    Conclusion & Outlook

    Cefazedone (Refosporen) is a robust first-generation cephalosporin with well-characterized mechanism and efficacy parameters. Its β-lactamase stability and broad-spectrum coverage ensure utility across research and clinical settings. Time-dependent pharmacodynamics (fT>MIC) should guide dosing and monitoring for reliable outcomes. Continued integration of validated analytical methods and standardized workflows, as enabled by suppliers like APExBIO, will support translational research and clinical implementation. For a data-driven perspective on its optimal application and comparison to related cephalosporins, see the Data-Driven Guide.